ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RNAC vs BBOT // RETURN ON INVESTED CAPITAL (ROIC)

Cartesian Therapeutics Inc. (NASDAQ) VS. BridgeBio Oncology Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RNAC 2 — BBOT 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNAC VS. BBOT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RNAC BBOT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 20.0 +20.20 RNAC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $191.8M $185.2M $6.6M RNAC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RNAC REV BBOT REV RNAC GROSS % BBOT GROSS % RNAC FCF BBOT FCF
FY 2025 $400.0K $408.3M — — -$79.4M -$114.5M
FY 2024 $38.3M $226.4M — — -$32.8M -$55.1M
FY 2023 $26.0M $116.7K — — -$51.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNAC // BETA —
BBOT // BETA —